Cargando…
MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses
With the clinical approval of T-cell–dependent immune checkpoint inhibitors for many cancers, therapeutic cancer vaccines have re-emerged as a promising immunotherapy. Cancer vaccines require the addition of immunostimulatory adjuvants to increase vaccine immunogenicity, and increasingly multiple ad...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437625/ https://www.ncbi.nlm.nih.gov/pubmed/36059502 http://dx.doi.org/10.3389/fimmu.2022.936129 |
_version_ | 1784781660605120512 |
---|---|
author | Taylor, David Meyer, Christian T. Graves, Diana Sen, Rupashree Fu, Juan Tran, Emily Mirza, Bilal Rodriguez, Gabriel Lang, Cara Feng, Hanwen Quaranta, Vito Wilson, John T. Kim, Young J. Korrer, Michael J. |
author_facet | Taylor, David Meyer, Christian T. Graves, Diana Sen, Rupashree Fu, Juan Tran, Emily Mirza, Bilal Rodriguez, Gabriel Lang, Cara Feng, Hanwen Quaranta, Vito Wilson, John T. Kim, Young J. Korrer, Michael J. |
author_sort | Taylor, David |
collection | PubMed |
description | With the clinical approval of T-cell–dependent immune checkpoint inhibitors for many cancers, therapeutic cancer vaccines have re-emerged as a promising immunotherapy. Cancer vaccines require the addition of immunostimulatory adjuvants to increase vaccine immunogenicity, and increasingly multiple adjuvants are used in combination to bolster further and shape cellular immunity to tumor antigens. However, rigorous quantification of adjuvants’ synergistic interactions is challenging due to partial redundancy in costimulatory molecules and cytokine production, leading to the common assumption that combining both adjuvants at the maximum tolerated dose results in optimal efficacy. Herein, we examine this maximum dose assumption and find combinations of these doses are suboptimal. Instead, we optimized dendritic cell activation by extending the Multidimensional Synergy of Combinations (MuSyC) framework that measures the synergy of efficacy and potency between two vaccine adjuvants. Initially, we performed a preliminary in vitro screening of clinically translatable adjuvant receptor targets (TLR, STING, NLL, and RIG-I). We determined that STING agonist (CDN) plus TLR4 agonist (MPL-A) or TLR7/8 agonist (R848) as the best pairwise combinations for dendritic cell activation. In addition, we found that the combination of R848 and CDN is synergistically efficacious and potent in activating both murine and human antigen-presenting cells (APCs) in vitro. These two selected adjuvants were then used to estimate a MuSyC-dose optimized for in vivo T-cell priming using ovalbumin-based peptide vaccines. Finally, using B16 melanoma and MOC1 head and neck cancer models, MuSyC-dose–based adjuvating of cancer vaccines improved the antitumor response, increased tumor-infiltrating lymphocytes, and induced novel myeloid tumor infiltration changes. Further, the MuSyC-dose–based adjuvants approach did not cause additional weight changes or increased plasma cytokine levels compared to CDN alone. Collectively, our findings offer a proof of principle that our MuSyC-extended approach can be used to optimize cancer vaccine formulations for immunotherapy. |
format | Online Article Text |
id | pubmed-9437625 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94376252022-09-03 MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses Taylor, David Meyer, Christian T. Graves, Diana Sen, Rupashree Fu, Juan Tran, Emily Mirza, Bilal Rodriguez, Gabriel Lang, Cara Feng, Hanwen Quaranta, Vito Wilson, John T. Kim, Young J. Korrer, Michael J. Front Immunol Immunology With the clinical approval of T-cell–dependent immune checkpoint inhibitors for many cancers, therapeutic cancer vaccines have re-emerged as a promising immunotherapy. Cancer vaccines require the addition of immunostimulatory adjuvants to increase vaccine immunogenicity, and increasingly multiple adjuvants are used in combination to bolster further and shape cellular immunity to tumor antigens. However, rigorous quantification of adjuvants’ synergistic interactions is challenging due to partial redundancy in costimulatory molecules and cytokine production, leading to the common assumption that combining both adjuvants at the maximum tolerated dose results in optimal efficacy. Herein, we examine this maximum dose assumption and find combinations of these doses are suboptimal. Instead, we optimized dendritic cell activation by extending the Multidimensional Synergy of Combinations (MuSyC) framework that measures the synergy of efficacy and potency between two vaccine adjuvants. Initially, we performed a preliminary in vitro screening of clinically translatable adjuvant receptor targets (TLR, STING, NLL, and RIG-I). We determined that STING agonist (CDN) plus TLR4 agonist (MPL-A) or TLR7/8 agonist (R848) as the best pairwise combinations for dendritic cell activation. In addition, we found that the combination of R848 and CDN is synergistically efficacious and potent in activating both murine and human antigen-presenting cells (APCs) in vitro. These two selected adjuvants were then used to estimate a MuSyC-dose optimized for in vivo T-cell priming using ovalbumin-based peptide vaccines. Finally, using B16 melanoma and MOC1 head and neck cancer models, MuSyC-dose–based adjuvating of cancer vaccines improved the antitumor response, increased tumor-infiltrating lymphocytes, and induced novel myeloid tumor infiltration changes. Further, the MuSyC-dose–based adjuvants approach did not cause additional weight changes or increased plasma cytokine levels compared to CDN alone. Collectively, our findings offer a proof of principle that our MuSyC-extended approach can be used to optimize cancer vaccine formulations for immunotherapy. Frontiers Media S.A. 2022-08-19 /pmc/articles/PMC9437625/ /pubmed/36059502 http://dx.doi.org/10.3389/fimmu.2022.936129 Text en Copyright © 2022 Taylor, Meyer, Graves, Sen, Fu, Tran, Mirza, Rodriguez, Lang, Feng, Quaranta, Wilson, Kim and Korrer https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Taylor, David Meyer, Christian T. Graves, Diana Sen, Rupashree Fu, Juan Tran, Emily Mirza, Bilal Rodriguez, Gabriel Lang, Cara Feng, Hanwen Quaranta, Vito Wilson, John T. Kim, Young J. Korrer, Michael J. MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses |
title | MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses |
title_full | MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses |
title_fullStr | MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses |
title_full_unstemmed | MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses |
title_short | MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses |
title_sort | musyc dosing of adjuvanted cancer vaccines optimizes antitumor responses |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437625/ https://www.ncbi.nlm.nih.gov/pubmed/36059502 http://dx.doi.org/10.3389/fimmu.2022.936129 |
work_keys_str_mv | AT taylordavid musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses AT meyerchristiant musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses AT gravesdiana musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses AT senrupashree musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses AT fujuan musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses AT tranemily musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses AT mirzabilal musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses AT rodriguezgabriel musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses AT langcara musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses AT fenghanwen musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses AT quarantavito musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses AT wilsonjohnt musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses AT kimyoungj musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses AT korrermichaelj musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses |